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1 | INTRODUC TION
In December 2019, a cluster of cases clinically similar to viral pneu-
monia but caused by a new coronavirus began to be identified in 
Wuhan, China. The World Health Organization (WHO) announced 
that the causative agent was a new type of coronavirus, which was 
labelled “novel coronavirus (COVID- 19),” and declared a pandemic 
on 12 March 2020.1
After transmission through close contact with respiratory droplets, 
the virus enters the cells through the angiotensin- converting enzyme 
2 (ACE 2) receptor and causes damage. As the ACE 2 receptor is dis-
tributed mainly in type 2 alveolar cells (AT 2 cells) in lung tissue, the pri-
mary target of COVID- 19 in the human body is the lungs.2 Therefore, 
the primary signs and symptoms observed in patients are those of viral 
upper respiratory disease such as fever, cough and dyspnea.3
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Aim: Dyspnea, a common symptom of novel coronavirus, can negatively affect sleep 
quality. The aim of this study was to evaluate the relationship between dyspnea se-
verity and sleep quality in patients with COVID- 19.
Study Design: A cross- sectional design was used.
Methods: Using the researcher's mobile phone, data were collected via an online 
questionnaire from patients (n = 100) who agreed to participate in the study. The 
data- collection form comprised three parts: a patient descriptive information form, 
the Dyspnea– 12 Questionnaire, and the Richards– Campbell Sleep Questionnaire 
(RCSQ).
Results: The mean age of patients was 46.39 ± 12.61 years and 66.0% were men. 
Patients who were treated in the intensive care unit had bachelor's degree or more 
and patients with comorbid diseases had low mean scores from the RCSQ and high 
mean scores from the Dyspnea– 12 Questionnaire (P < .001, P < .001; P = .047, 
P < .001; P < .001, P < .001, respectively). Patients who were not receiving oxygen 
therapy had higher RCSQ mean scores and lower Dyspnea– 12 Questionnaire scores 
(P < .001, P < .001; P < .001, P < .001, respectively). There was a strong negative 
relationship between the total scores obtained from the RCSQ and the Dyspnea– 12 
Questionnaire (r =	−.701,	P < .001).
Conclusions: Sleep quality is affected by dyspnea severity in patients with COVID- 19. 
Sleep quality and dyspnea severity are also influenced by quite different factors, and 
these should be addressed and eliminated by nurses as part of a holistic approach. 
The results of this study will help nurses, especially those providing treatment and 
care for patients with COVID- 19, to identify the factors affecting dyspnea and sleep 
quality and to plan, implement and evaluate nursing interventions that will reduce 
their workload.
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Dyspnea, a symptom seen in about 40% of patients, nega-
tively affects quality of life by causing difficulty performing daily 
life activities as a result of sleep problems, increased care de-
pendency, depression and anxiety.4,5 Sudden or severe dyspnea 
in COVID- 19 patients causes an increase in lung lesions, leading 
to further aggravation of the disease.6 About 50% of COVID- 19 
patients with severe dyspnea have acute respiratory distress 
syndrome (ARDS), difficult- to- correct metabolic acidosis and co-
agulopathy, and a number of these may die in the first week after 
disease onset.7
New infectious diseases like severe acute respiratory syn-
drome (SARS) and COVID- 19 affect patients not only physically 
but also psychologically, causing anxiety, depression and sleep 
disorders in the treatment process.6,8 Sleep not only affects 
quality of life but also plays a role in preserving immune function 
and reducing the transmission of viral infections; it is also vital 
to maintaining mental well- being.8,9 A decrease in sleep quality 
increases dyspnea by exacerbating pre- existing hypoxemia and 
hypercapnia, thereby increasing the patient's anxiety and depres-
sion levels.10
In the COVID- 19 treatment process, patients are isolated, typ-
ically in intensive care units (ICUs).6,11 Lai et al (2020)12 reported 
that isolated individuals experienced high levels of depression, 
anxiety and stress; insomnia; and a decrease in their sleep qual-
ity. The required treatment of this highly contagious disease means 
that being alone for an extended time in a room increases these 
symptoms.13 To provide personal and quality patient care and to 
manage dyspnea effectively, nurses should rate dyspnea severity 
and measure sleep quality in each COVID- 19- positive patient and 
focus on the affecting factors. The aim of this study is to evaluate 
the relationship between dyspnea severity and sleep quality in pa-
tients with COVID- 19.
2  | METHODS
2.1 | Aims
This study was conducted to evaluate the relationship between 
dyspnea severity and sleep quality in patients with COVID- 19.
2.2 | Research questions
What is the severity of dyspnea in patients with COVID- 19?
How is the sleep quality of patients with COVID- 19?
Is there a relationship between dyspnea severity and sleep qual-
ity in patients with COVID- 19?
2.3 | Study design
This is a descriptive and cross- sectional study.
2.4 | Settings and sample of the study
Participants in this study were adult patients who were diagnosed 
with COVID- 19 and received inpatient treatment in a training and 
research hospital. The population of this study was N = 122 patients. 
A total of 100 volunteer patients who met the following criteria 
participated: being in a COVID- 19 clinic or in second- line intensive 
care where patients with COVID- 19 were being treated between 1 
and	30	June	2020;	having	spent	at	 least	one	night	 in	the	hospital;	
being conscious (with a Glasgow Coma Scale score of 13 or above); 
being able to communicate verbally; having complained of dyspnea; 
and having no obstacles to participating in the study in terms of the 
treatment process. The presence of dyspnea, which is one of the 
inclusion criteria, was asked to the patients as “Have you ever had 
trouble in breathing after being diagnosed with COVID- 19”? in the 
patient descriptive information form. Patients who stated that they 
had respiratory distress were included in the study. Also, research-
ers checked the oxygen saturation levels of the patients and patients 
with oxygen saturation below 90% once from the date of patient 
admission were included in the study.
Since COVID- 19 is a new epidemic disease that first appeared in 
December 2019, there is, to the best of our knowledge, no study to 
date that has examined the relationship between dyspnea and sleep 
quality in patients with COVID- 19. With no prior study to reference 
for calculating the sample, a power analysis of the study was per-
formed with 100 patients by taking into consideration the number 
of questionnaire items. In a power analysis performed with a sample 
What’s known
• New infectious disease COVID- 19 affects patients not 
only physically but also psychologically, causing anxi-
ety, depression, and sleep disorders in the treatment 
process.
• Sleep not only affects quality of life but also plays a role 
in preserving immune function and reducing the trans-
mission of viral infections; it is also vital to maintaining 
mental well- being.
• About 50% of COVID- 19 patients with severe dyspnea 
have acute respiratory distress syndrome.
What’s new
• Patients with COVID- 19 were found to suffer from poor 
sleep quality, and the more severe patients’ dyspnea 
was, the lower their sleep quality was.
• Dyspnea and sleep quality were affected by many fac-
tors in the pandemic survey.
• Elderly patients, patients with a comorbid disease, 
smokers, those who received continuous or intermittent 
oxygen therapy using non- invasive CPAP masks, and 
those hospitalized in the ICU had more severe dyspnea.
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size of 100 patients, the correlation between the Richards– Campbell 
Sleep Questionnaire (RCSQ) and the Dyspnea- 12 Questionnaire was 
calculated as r = .0703; the effect size is 0.83; and the power of the 
study is 90% with a confidence interval of 95%.
2.5 | Data- collection tools
The data- collection form comprised three parts: a patient descrip-
tive information form, the Dyspnea- 12 Questionnaire and the RCSQ. 
Using the researcher's mobile phone, data were collected via an on-
line questionnaire from patients (n = 100) who agreed to participate 
in the study. The researcher visited the clinic and intensive care unit, 
using personal protective equipment between 09.00 and 12.00 am 
After informing the patients face to face, the researcher collected 
the data with an online questionnaire. The researcher informed 
the patients about the study after taking appropriate preventive 
measures and maintaining social distance. A link was sent to those 
patients who agreed to participate via an instant messaging applica-
tion, and they completed the questionnaire in about 10- 15 minutes 
after selecting the option “I was informed of and agree to participate 
in the study.”
2.5.1 | Patient	descriptive	information	form
The patient descriptive information form, the first part of the 
data- collection process, was developed by the researchers based 
on the literature review and included the following: gender, date 
of birth, educational level, name of clinic where the individual 
was admitted, the presence of any comorbid diseases, financial 
status, smoking status, whether the patient was receiving oxygen 
support therapy and, if so, which type, sleep habits, and whether 
the patient felt rested upon awakening.6,14- 16 The same treatment 
protocol were applied to patients who received COVID- 19 treat-
ment. In this scope, the following drugs were given to the patients: 
Favipiravir 200 mg 2 × 8 tablets first day; 2 × 3 tablets after 1st 
day, Paracetamol 500 mg tablet 1 × 1, Hydroxychloroquine 
Sulfate 200 mg tablet 1 × 1. In addition, antibiotics were added to 
the treatment plan of intensive care patients resulting from sec-
ondary infections.
2.5.2 | Dyspnea-	12	questionnaire
This 12- item questionnaire was developed by Yorke, Moosavi, 
Shuldham	and	Jones17 to measure the severity of dyspnea. The first 
seven items of this 4- point Likert- type scale (0 = none, 1 = mild, 
2 = moderate, 3 = severe) ask patients about physical difficulties 
they experience because of dyspnea by evaluating the following 
factors: whether or not an inhaled breath goes throughout their 
lungs, if they have shortness of breath, if they have difficulty catch-
ing their breath, if breathing requires greater effort, if they feel like 
they are not getting enough air, if breathing causes discomfort, and 
if breathing is exhausting. The remaining five items of the question-
naire focus on the affective aspects of breathing such as depres-
sion, misery, distress, agitation, and irritation. The maximum scores 
for the physical and affective aspects of the questionnaire are 21 
and 15, respectively. The minimum total score for the question-
naire is 0, whereas the maximum total score is 36. The higher the 
score, the more severe the dyspnea. The original study reported 
the Cronbach's alpha of this questionnaire as 0.90.17 The adapta-
tion of the Dyspnea– 12 Questionnaire to Turkish and validity and 
reliability	studies	were	conducted	by	Gok	Metin	and	Helvacı,16 who 
found Cronbach's alpha to be 0.97. In this study, Cronbach's alpha 
was found to be 0.99.
2.6 | Richards– Campbell Sleep questionnaire 
(RCSQ)
The RCSQ is a six- item questionnaire that assesses the depth of 
night sleep, sleep onset latency, frequency of awakenings, time 
spent awake after waking up, sleep quality and level of ambient 
noise. Scores in the range of 0- 25 refer to “very poor sleep” and 
76- 100 to “very good sleep”. Although, there is no cut- off value for 
poor and good, it was stated that the higher the score, the higher the 
sleep quality.18 The adaptation of the RCSQ to Turkish and its valid-
ity and reliability studies were conducted by Ozlu and Ozer,19 and 
Cronbach's alpha was found to be 0.91, showing that the RCSQ is a 
highly reliable questionnaire with internal consistency. In this study, 
Cronbach's alpha was found to be 0.93.
2.7 | Data analysis
The data were analyzed using SPSS 22 Statistics software pack-
age.20 Number, mean, standard deviation, minimum, maximum, 
and frequency were used in the descriptive statistical analyses in 
the study. The data were tested for normal distribution using the 
Shapiro– Wilk test and skewness and kurtosis values. Student's t test, 
one- way ANOVA and Kruskal– Wallis tests were used to compare 
the questionnaire mean scores of two independent groups and three 
or more groups, respectively. Bonferroni correction was applied to 
determine which group caused the difference in the three- group 
comparison. To clarify which group caused the difference, the statis-
tically significant differences were indicated in the tables using the 
superscripts “a, b, c, d” and codes such as “a- b, c” when three or more 
groups were compared. For example, the code “a- b, c” means that 
there is a statistically significant difference between the variable “a” 
and the variables “b” and “c” but no statistically significant difference 
between “b” and “c.” The relationships between the total score for 
the RCSQ and the total score for the Dyspnea– 12 Questionnaire and 
its sub- dimensions (physical and affective) were determined using 
the Pearson correlation analysis. The statistical significance was set 
at P < .05 in all tests.
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2.8 | Ethical considerations of the study
The study was initiated after receiving approval from the local eth-
ics committee of the Non- Interventional Research Ethics Committee 
of the faculty of health sciences of a university (Date:27.05.2020, 
No:0028) and written institutional permission from the training and 
research hospital where the study was conducted. The study was 
conducted in line with the principles of the Helsinki Declaration. 
Permission was received via e-mail from the authors who conducted 
validity and reliability studies of the Dyspnea– 12 Questionnaire and 
the RCSQ.
3  | RESULTS
This study was completed with 100 patients diagnosed as COVID- 
19- positive; 33.0% were receiving care and treatment in the ICU and 
67.0% in the clinics. Their mean hospital stay was 3.52 ± 1.64 days 
(Min:2, Max:12) (Table 1).
The patients’ mean age was 46.39 ± 12.61 years, and 66.0% 
were men. Of 100 patients, 29.9% had Diabetes Mellitus and 60.0% 
were smokers. When the patients were evaluated in terms of oxy-
gen therapy, it was found that 35.0% received intermittent oxygen 
therapy, while more than half (55.8%) received nasal cannula oxygen 
therapy (Table 1).
The patients’ RCSQ mean total score was calculated as 
46.76 ± 15.70 (Min: 6, Max: 92). For the Dyspnea– 12 Questionnaire, 
mean total score was 12.34 ± 12.44 (Min: 0, Max: 36), and the 
mean scores for the physical and affective sub- dimensions were 
7.26 ± 7.24 (Min: 0, Max: 21) and 5.08 ± 5.24 (Min: 0, Max: 15), 
respectively.
Those patients being treated in the ICU had a significantly 
lower RCSQ mean total score than those being treated in the clinic 
(t =	 −7.591,	 P < .001), and illiterate patients had a significantly 
lower RCSQ mean total score than those having a bachelor's de-
gree or higher (f = 2.741, P < .047). Furthermore, the RCSQ mean 
total score of those who did not have a comorbid disease was sig-
nificantly higher than those who had one (t = 3.88, P < .001); the 
RCSQ mean total score of those who could communicate with their 
family by phone was significantly higher than for those who could 
not (t =	−5.949,	P < .001); the RCSQ mean total score of those who 
reached the nurses by using the call button was significantly higher 
than those who called out to them (t = 2.309, P < .023). The RCSQ 
mean total score of the patients who did not receive oxygen therapy 
was significantly higher than for those who received continuous and 
intermittent oxygen therapy (f = 33.862, P < .001) and those who 
received oxygen therapy via nasal cannula, simple mask, and non- 
invasive continuous positive airway pressure (CPAP) (f = 25.638, 
P < .001) (Table 2).
The patients in the ICU (t = 10.373, P <.001), those in the age 
group 65 years and older (t = 2.847, P < .05), and those with co-
morbid diseases (t =	 −7.119,	 P < .001) had a statistically signifi-
cantly higher mean total score on the Dyspnea– 12 Questionnaire. 
It was found that the dyspnea scale was affected by the smoking 
status, and the difference was because of the difference in mean 
scores between smokers and non- smokers (X2= 10.798, P = .005). 
Furthermore, it was found that dyspnea severity varied depend-
ing on educational status, with those having a bachelor's degree 
or higher having a lower mean total score on the Dyspnea– 12 
Questionnaire than those who were unable to read or write and 
those who were primary- school graduates (f =	−6.260,	P < .001). 
When the Dyspnea– 12 Questionnaire mean scores of the patients 
were compared in regard to the type and frequency of oxygen ther-
apy, it was found that those who did not receive oxygen therapy 
had a significantly lower score than those receiving it either contin-
uously or intermittently (f = 70.912, P < .001) and those receiving it 
via nasal cannula, simple mask, and non- invasive CPAP. Moreover, 
those who received oxygen therapy using non- invasive CPAP had 
a significantly lower score than those receiving it via nasal cannula 
and simple mask (f = 115.074, P < .001). No statistically significant 
differences were found between the mean total scores obtained 
from the RCSQ in terms of gender, age, smoking status and finan-
cial status (P > .05) (Table 3).
There was a statistically significant strong negative correla-
tion between the total score for the Richards– Campbell Sleep 
Questionnaire and the total score for the Dyspnea– 12 Questionnaire 
and its sub- dimensions (physical and affective) (r =	−0.701,	P < .001). 
It was also found that the higher the patients’ dyspnea severity was, 
the lower their sleep quality was (Table 4).
4  | DISCUSSION
In this study, which was conducted to evaluate the relationship be-
tween dyspnea severity and sleep quality in patients with COVID- 19, 
it was found that, among those patients whose sleep quality was 
poor, the more severe their dyspnea was, the lower their sleep qual-
ity was. In the previous studies, dyspnea was defined as “the perma-
nent and progressive airflow limitation occurring as a result of the 
inflammatory response in the lungs”.
and reported to be associated with numerous symptoms includ-
ing cough, fatigue, sleep problems, anxiety and depression.10,11,21
In this study, more than half of the patients with COVID- 19 
were found to be men with comorbid diseases such as diabetes 
mellitus, chronic obstructive pulmonary disease (COPD), and hy-
pertension. Thus, it can be hypothesized that the presence of a 
comorbid disease generally exacerbates patients’ COVID- 19 
symptoms, leading to hospitalization for treatment. A similar pa-
tient population was reported in studies conducted in China,22 
the US23 and India.24 In the present study, more than half of the 
patients (60.0%) were non- smokers, and the majority of smokers 
quit smoking during this period, which aligned with the results of 
otherstudies.25,26
While most of the patients were treated in the clinical services, 
those who were older were treated in the ICUs. The previous studies 
also reported that the majority of the patients were treated in clinics, 
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Mean ± SD (Min- Max) Mean ± SD (Min- Max) Mean ± SD (Min- Max)
Mean hospital stay (d) 4.21 ± 1.59 (2- 8) 3.18 ± 1.57 (2- 12) 3.52 ± 1.64 (2- 12)
Mean age (y) 53.55 ± 8.91 (37- 72) 42.84 ± 12.73 (20- 90) 46.39 ± 12.61 (20- 90)
n % n % n %
Age groups
18- 64 y 28 84.8 63 94.0 91 91.0
65 y and over 5 15.2 4 6.0 9 9.0
Gender
Women 12 36.4 22 32.8 34 34.0
Men 21 63.6 45 67.2 66 66.0
Educational status
Illiterate 6 18.2 8 11.9 14 14.0
Primary School 22 66.7 27 40.3 49 49.0
High School 5 15.1 14 20.9 19 19.0
Bachelor's Degree or More 0 0 18 26.9 18 18.0
Financial status
My income is more than my living 
expenses
6 18.2 4 6.0 10 10.0
My income enough to cover my 
living expenses
27 81.8 54 80.6 81 81.0
My income is not enough to cover 
my living expenses
0 0 9 13.4 9 9.0
Comorbid diseases*
Diabetes mellitus 18 32.1 5 23.8 23 29.9
Chronic obstructive pulmonary 
disease
16 28.6 6 28.6 22 28.6
Hypertension 10 17.9 4 19.1 14 18.2
Heart Failure 6 10.7 2 9.5 8 10.4
Renal Failure 2 3.6 2 9.5 4 5.2
Other 4 7.1 2 9.5 6 7.7
Smoking status
I smoke 14 42.4 20 29.9 34 34.0
I do not smoke 14 42.4 46 68.7 60 60.0
I quit smoking 5 15.2 1 1.4 6 6.0
Communication with the family
I do not communicate 28 84.8 2 3.0 30 30.0
I communicate over the phone 5 15.2 65 97.0 70 70.0
The way of reaching out to the 
nurses
By using the call button 1 3.0 32 47.8 33 33.0
By calling out 32 97.0 35 52.2 67 67.0
Frequency of oxygen therapy
Continuously 13 39.4 4 6.0 17 17.0
Intermittently 19 57.6 16 23.9 35 35.0
Not Receiving 1 3.0 47 70.1 48 48.0
(Continues)
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and those with more- severe conditions were advanced- age patients 
who were being treated in ICUs.22,26
Han et al (2020)27 reported that patients with COVID- 19 experi-
enced problems such as depression, anxiety and insomnia. Another 
study reported that sleep quality was low among individuals who 
isolated themselves during the COVID- 19 outbreak.8 By contrast, 
a study conducted in Italy reported that the sleep– wake rhythms of 
patients changed significantly and their sleep quality decreased.28 
The participants of this study stated that the ambient noise in the 
hospital was not especially disturbing; however, they evaluated their 
overall sleep quality as poor. This situation may be associated with 
the fact that factors such as the absence of definitive treatments and 
a vaccine for COVID- 19, uncertainty about the long- term effects of 
the disease, patients’ loss of their usual roles in their families and 
everyday lives, and loneliness can lead to anxiety and disordered-
sleep.11,29 It was found that patients with less education and those 
with a comorbid disease experienced poorer sleep quality than those 
whose education included a bachelor's degree or higher and those 
without comorbid disease, respectively. Moreover, patients in the 
clinical services reported better sleep quality than those in the ICU. 
This outcome was expected because patients with little education 
tend to know less about COVID- 19 and, thereby, have greater lev-
els of fear about the unknown. Those patients with comorbid dis-
eases have more severe symptoms of COVID- 19; patients in ICUs 
are exposed to more medical interventions and stimuli; and their 
Dyspnea– 12 Questionnaire scores are higher because of the sever-
ity of their status.9,29
The RCSQ mean scores of those who could communicate 
with their families and reach the nurses using the call button 
were found to be significantly higher. Nurses, as the healthcare 
professionals responsible for 24- hour patient care, should in-
form patients about the use of call buttons in detail, and insti-
tutions should provide the necessary regulations to ensure this. 
Necessary precautions should be taken to improve the social and 
mental health status of those who are isolated because of infec-
tious diseases and to solve problems that may be encountered in 
the nursing process. Social service specialists, psychologists and 
nurses should manage this situation in a multidisciplinary way and 
encourage patients to communicate with their family members 
using technology. These approaches are designed to improve 
mental health and sleep and, thus, can increase resistance to in-
fectious diseases and, by doing so, boost immune function.8,9,30 
It was found that patients receiving continuous and intermittent 
oxygen therapy, especially those receiving oxygen therapy using 
non- invasive CPAP, had lower RCSQ scores than those not re-
ceiving oxygen supportive therapy. Because non- invasive CPAP 
therapy must also be used at night and the masks used can cause 
skin abrasions because of pressure, patient compliance with 
treatment and impaired comfort may result compared with the 
nasal cannula and mask applications. Fatigue and dyspnea lead 
to poor sleep quality and, as a result, negatively affect quality 
of life.4,31 This finding was also supported by this study, which 
revealed a strong correlation between the mean total scores ob-
tained from the RCSQ, the Dyspnea– 12 Questionnaire and its 
sub- questionnaires.
When the Dyspnea– 12 Questionnaire mean scores were an-
alyzed, it was found that patients age 65 and older, patients 
with a comorbid disease, smokers, those who received contin-
uous or intermittent oxygen therapy using non- invasive CPAP 
masks and those hospitalized in the ICU had higher mean scores. 
The studies examining the dyspnea severity in patients with 
COPD reported that their health status worsened and dyspnea 
severity increased with age.32- 34 Smoking, the most important 
risk factor for diseases causing lung damage, significantly af-
fects patients’ health status, dyspnea severity and quality of 
life. Several studies reported that the increase in the amount 
and duration of smoking worsened health status,35,36 increased 
dyspnea severity34 and reduced quality of life4,32 in patients 
with COPD. In line with the literature, our study also revealed 
that patients’ health status worsened and dyspnea severity in-
creased in individuals with COVID- 19 who smoked. The oxidant 
substances in cigarette smoke and the abnormal inflammatory 
process developing in response to oxidant stress are respon-
sible for lung damage in patients.37 In their systematic review, 
Wang et al22 reported that patients with COVID- 19 and a co-
morbid disease had higher acute organ failure and morbidity 
and experienced a more serious disease process. Therefore, we 








Mean ± SD (Min- Max) Mean ± SD (Min- Max) Mean ± SD (Min- Max)
Type of the oxygen therapy 
received
Nasal Cannula 10 31.2 19 95.0 29 55.8
Simple Mask 4 12.5 1 5.0 5 9.6
Non- invasive CPAP 18 56.3 0 0 18 34.6
Abbreviations: COPD, chronic obstructive pulmonary disease, CPAP, continuous positive airway pressure.
*Options were multipy (participants may have more than one comorbid disease).
TA B L E  1   (Continued)
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and older, those who needed oxygen support, and those who 
received intensive care treatment had more- severe dyspnea 
since they had more- severe respiratory system- related symp-
toms of COVID- 19.
In this study, a strong negative correlation was found be-
tween the total scores obtained from the RCSQ and those 
obtained from the Dyspnea– 12 Questionnaire and its sub- 
questionnaires. This means that patients with COVID- 19 who 
have a high level of dyspnea also suffer from low- quality sleep. 
Ora et al38 reported the prevalence of dyspnea as 31.8% in 
COVID- 19 patients, but did not reveal a relationship between 
dyspnea	and	neurological	symptoms.	Jiang	et	al	(2020),39 on the 
other hand, evaluated the relationship between mental health 
status and sleep quality of COVID- 19. The study findings reveal 
that environmental stressors, physical illness, separation from 
family and friends and other comorbid psychological problems 
lead	to	sleep	disorders.	In	this	study,	Jiang	et	al39 found that the 
presence of comorbid diseases reduces sleep quality. No study 
in the literature has investigated the relationship between sleep 
quality and dyspnea associated with the lung damage caused 
by COVID- 19. Budhiraja et al40 found that 27.3% of 183 partic-
ipants with COPD had insomnia (a chronic sleep disorder asso-
ciated with impaired daytime functioning). In diseases involving 
the respiratory system, the cause of atonia in skeletal muscles, 
including the accessory muscles of breathing, is not fully known. 
In this regard, deep desaturation can occur during REM sleep, 
and mucus plugging and/or hypersecretion may develop during 
sleep.41 In addition to these situations, the sleep– wake cycle 
changes when patients are treated at the hospital. Because of 
the interventions applied during the hospital stay, individuals 
may have to be awakened frequently. In the hospital environ-
ment, numerous factors including noise, light, nursing interven-
tions, invasive interventions, intermittent or continuous oxygen 
support, loss of privacy, and being away from one's home may 
contribute to impaired sleep quality.19
TA B L E  2   Comparison of the RCSQ mean scores of the 
patients with COVID- 19 by some of their descriptive and medical 





Intensive care 33.21 + 13.10 t =	−7.591
P < .001**Clinical service 53.43 + 12.23
Age groups
18- 64 y 47.56 ± 15.88 t = 1.634
P =.05665 y and over 38.67 ± 11.48
Gender
Women 47.88 ± 18.23 t = 0.511
P = .610Men 46.18 ± 14.28
Educational status
Illiteratea 40.85 ± 16.59 f = 2.741
P = .047*
(a- d)**
Primary schoolb 44.53 ± 17.62
High schoolc 49.68 ± 9.667




My income is more 
than my living 
expenses
56.67 ± 11.53 f = 2.103
P = .128
My income enough 
to cover my living 
expenses
46.02 ± 16.37
My income is not 




Yes 41.22 ± 17.34 t = 3.66
P <.001***No 52.08 ± 11.85
Smoking status
I smoke 43.76 ± 16.93 X2 = 3.683
P = .159I do not smoke 48.70 ± 15.29
I quit smoking 44.33 ± 10.76
Communication with 
the family
I communicate with 
my family over the 
phone
52.03 ± 13.52 t =	−5.949
P < .001***
I do not communicate 34.47 ± 13.53
The way of reaching out 
to the nurses
By using the call 
button
51.82 ± 9.72 t = 2.309
P =.023*
By calling out 44.27 ± 17.46
Frequency of oxygen 
therapy
Continuouslya 35.88 ± 12.35 f = 33.862
P <.001***
(c- a,b)**
Intermittentlyb 37.77 ± 13.34





Type of the oxygen 
therapy received
Nasal cannulaa 40.14 ± 12.85 f = 25.638
P <.001***
(d- a,b,c)**
Simple maskb 40.00 ± 7.07
Non- invasive CPAPc 31.56 ± 12.95
Not receivingd 57.17 ± 11.18
Abbreviations: t, independent two- sample t test; f, single directional 
variance analysis; X2, Kruskal– Wallis test.
*Statistical significance at P < .05. 
**The difference between the groups expressed by the letters 
is statistically significant at P < .05 after Bonferroni correction. 
***Statistical significance at P < .001.
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4.1 | Limitations
Our study has several limitations. The study was conducted in a 
single center. To overcome this limitation and increase contribu-
tions to the literature, the sample can be diversified by incorpo-
rating the intervention studies in hospitals in different regions. In 
this study, a limited number of factors such as Body Mass Index, 
drugs affecting sleep, psychosocial factors and patient's position 
affecting sleep quality and dyspnea were addressed. In addition, 
in this study Dispnea- 12 Questionnaire and RCSQ were applied 
only one time.
5  | CONCLUSION
In this study, patients with COVID- 19 were found to suffer from 
poor sleep quality, and the more severe patients’ dyspnea was, the 
lower their sleep quality was. Dyspnea and sleep quality are affected 
by many factors. Diagnosis and treatment of dyspnea are vital to 
ensure high- quality sleep and, thus, improve the individual's qual-
ity of life and health status. Identification and treatment of dyspnea 
and insomnia contribute positively to the individual's health status 
by increasing immunity, especially during stressful times such as 
the COVID- 19 pandemic. The results of this study will help nurses, 
especially those providing treatment and care for patients with 
COVID- 19, to identify factors that affect dyspnea and sleep qual-
ity and to plan, implement and evaluate nursing interventions that 
will reduce their workloads. Furthermore, since long- term effects 
of COVID- 19 on patients are currently unknown, the results of this 
study are also important for identifying patients’ experiences during 
their hospital stay. Different factors affecting dyspnea and sleep can 
be investigated, and observational and experimental studies can be 
conducted in which patients are followed up for longer periods of 
time.
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Intensive care 25.76 ± 9.91 t = 10.373
P < .001***Clinical service 5.73 ± 7.08
Age groups
18- 64 y 11.26 ± 12.05 t =	−2.847
P = .005*65 y and over 23.22 ± 11.67
Gender
Women 12.56 ± 13.16 t = 0.126
P = .900Men 12.23 ± 12.15
Educational status
Illiteratea 18.29 ± 14.00 f = 6.260
P < .001***
(d- a,b)**
Primary Schoolb 15.33 ± 13.16
High Schoolc 8.11 ± 7.61




My income is more 
than my living 
expenses
6.67 ± 7.89 f = 2.858
P = .062
My income enough 
to cover my living 
expenses
12.05 ± 12.53
My income is not 




Yes 19.71 ± 12.69 t =	−7.119
P < .001***No 5.25 ± 6.88
Smoking status
I smokea 15.50 ± 10.67 X2 = 10.798
P = .005*
(a- b)**
I do not smokeb 9.58 ± 12.31
I quit smokingc 22.00 ± 15.95
Frequency of oxygen 
therapy
Continuouslya 20.06 ± 7.51 f = 70.912
P < .001***
(c- a, b)**
Intermittentlyb 22.17 ± 11.62
Not receivingc 2.44 ± 3.93
Type of the oxygen 
therapy received
Nasal Cannulaa 15.69 ± 8.53 f = 115.074
P < .001***
(d- a, b, c)**
(c- a, b)**
Simple maskb 18.00 ± 5.09
Non- invasive CPAPc 31.78 ± 5.21
Not receivingd 2.44 ± 3.93
Abbreviations: t, independent two- sample t test; f, single directional 
variance analysis; X2, Kruskal– Wallis test.
*Statistical significance at P < .05. 
**The difference between the groups expressed by the letters 
is statistically significant at P < .05 after Bonferroni correction. 
***Statistical significance at P < .001.
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participants had to fill to agree that they understood and volun-
teered to participate.
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